Which antibiotic provides coverage for Pseudomonas aeruginosa and Moraxella catarrhalis?

Antibiotics Covering Both Pseudomonas and Moraxella

For empiric coverage of both Pseudomonas aeruginosa and Moraxella catarrhalis, use a respiratory fluoroquinolone (ciprofloxacin or levofloxacin 750 mg) or an antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, ceftazidime, or a carbapenem).

Clinical Context and Antibiotic Selection

The choice of antibiotic depends critically on the clinical setting and severity of infection:

For Community-Acquired Infections (Outpatient)

• Ciprofloxacin 500-750 mg twice daily provides excellent coverage for both organisms 1, 2
• Levofloxacin 750 mg daily is an alternative fluoroquinolone option 3
• Moraxella catarrhalis is susceptible to ciprofloxacin (99%), cefuroxime (99%), and amoxicillin-clavulanate (100% when beta-lactamase producing) 4

For Hospital-Acquired Pneumonia or Severe Infections

When Pseudomonas risk factors are present (prior IV antibiotics within 90 days, structural lung disease, high mortality risk), use dual antipseudomonal coverage 3:

Preferred regimens:

• Piperacillin-tazobactam 4.5 g IV q6h PLUS ciprofloxacin 400 mg IV q8h or levofloxacin 750 mg IV daily
• Cefepime 2 g IV q8h or ceftazidime 2 g IV q8h PLUS a fluoroquinolone
• Meropenem 1 g IV q8h or imipenem 500 mg IV q6h PLUS a fluoroquinolone

For Bronchiectasis with Both Organisms

• Ciprofloxacin is the oral agent of choice when Pseudomonas is suspected 1, 2
• Amoxicillin-clavulanate 625 mg three times daily covers Moraxella but NOT Pseudomonas 2
• For exacerbations requiring IV therapy: antipseudomonal beta-lactam (ceftazidime, piperacillin-tazobactam, or meropenem) for 14 days 2

Key Resistance Considerations

Moraxella catarrhalis:

• Over 80% produce beta-lactamase, making ampicillin/amoxicillin ineffective 4
• Remains highly susceptible to amoxicillin-clavulanate, cefuroxime, fluoroquinolones, and macrolides 5, 4

Pseudomonas aeruginosa:

• Newer beta-lactam/beta-lactamase inhibitor combinations show excellent activity: ceftazidime-avibactam (95.8-97.3%), ceftolozane-tazobactam (96.0-98.3%), and imipenem-relebactam (97.6-98.7%) 6
• Ciprofloxacin resistance can develop during monotherapy, particularly in immunocompromised hosts 7
• Dual therapy is recommended for severe infections to prevent resistance emergence 8, 3

Critical Pitfalls to Avoid

1. Do not use macrolides alone - while effective against Moraxella, they have no Pseudomonas activity 2
2. Avoid aminoglycoside monotherapy except for urinary tract infections 9
3. Do not use standard cephalosporins (ceftriaxone, cefotaxime) - they lack Pseudomonas coverage despite covering Moraxella 3
4. Beware of fluoroquinolone monotherapy in severe Pseudomonas infections due to rapid resistance development 7

Treatment Duration

• Standard duration: 14 days for infections involving Pseudomonas 2
• 7-10 days may suffice for mild infections without Pseudomonas 1
• Longer courses (10-14 days) for bloodstream infections and hospital-acquired pneumonia 9

The most practical single-agent option for outpatient empiric coverage is ciprofloxacin 500-750 mg twice daily, while hospitalized patients with severe infection should receive dual antipseudomonal therapy with a beta-lactam plus fluoroquinolone 8, 3.